Johnson & Johnson pauses vaccine rollout due to blood clotting concerns

As the U.S. works towards vaccinating all willing participants by May, Johnson & Johnson had to press pause on their vaccination efforts. The Virginia Department of Health released the following statement on the issue. Please note that if you were scheduled for a Johnson & Johnson vaccine, you will be notified for a date to reschedule your appointment.

COVID-19 vaccine injection

Operations were halted after it was discovered that six women, ages 18 to 48, developed a rare blood-clotting disorder after getting the vaccine. The condition, though rare, is severe. One woman has died, and another has been hospitalized in critical condition. The clotting seemed to take effect 6-13 days after the vaccination.

Johnson & Johnson released a statement that said there is “no clear causal relationship” that has been identified between the vaccine and the blood clots. They are currently reviewing the cases with European health authorities, and decided to delay the rollout of its vaccine in Europe.

“Right now, these adverse events appear to be extremely rare,” the FDA said in a joint statement with the CDC. “COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously.”